【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

為什麼 CD47 標靶藥物被稱為生技界的「百慕達三角洲」？過去無數國際大藥廠折戟沉沙的領域，漢康生技竟能以 2.02 億美金成功授權，並開發出改寫產業標準的 3.5 代新藥 HCB101？
本集我們特別邀請到漢康生技研發長翟文武博士。他擁有英國劍橋大學與美國 UCSF 頂尖研究背景，並曾在輝瑞、羅氏擔任要職的他，將深度解析漢康如何利用 FBDB 平台與 AI 建模技術，解決 CD47 藥物最致命的「溶血毒性」痛點。

精彩內容：

• 解密 CD47 通路： 癌細胞如何利用「別吃我」訊號躲避免疫系統？

• 破解前車之鑑： 第一、二代藥物為何失敗？漢康 3.5 代藥物的差異化優勢在哪？

• AI 與抗體工程： 如何從收錄 1.8億筆資料庫中篩選出兼具「強效」與「安全」的分子？

• 以終為始的 CMC 製程： 為什麼「產量 6 g/L」與「自主掌握製程」是商業成功的基石？

• 未來的藍圖： HCB101 在頭頸癌、淋巴瘤與胃癌的驚人臨床表現，以及自體免疫疾病的新布局。

這不只是關於一場抗癌革命的紀錄，更是生技平台化轉型的經典案例。無論你是投資人、專業醫療從業人員，還是關心醫療科技發展的聽眾，都不容錯過！

【About This Episode】
Why is the CD47 target often called the "Bermuda Triangle" of drug development? While global pharmaceutical giants have struggled in this field, how did HanchorBio secure a $202 million licensing deal and develop HCB101, a 3.5-generation drug that is rewriting industry standards?
In this episode, we are honored to host Dr. Wenwu Zhai, Chief Research Officer of HNK Biotech. With a prestigious background from the University of Cambridge and UCSF, and leadership experience at Pfizer and Roche, Dr. Zhai provides a deep dive into how HNK utilizes its FBDB platform and AI modeling to solve the fatal "hemolytic toxicity" flaw that plagued previous generations of CD47 drugs.

【Key Takeaways】

• Decoding CD47: How cancer cells use the "Don't Eat Me" signal to evade the immune system.

• Learning from the Past: Why 1st and 2nd gen drugs failed, and the differentiated advantages of HNK’s 3.5-gen approach.

• AI & Antibody Engineering: The process of screening 1.8 X 10^8 molecules to find the perfect balance of "potency" and "safety."

• "Beginning with the End in Mind" (CMC): Why 6 g/L yield and in-house process control are the cornerstones of commercial success.

• The Future Roadmap: HCB101’s remarkable clinical performance in head and neck cancer, stomach cancer and lymphoma, and its strategic expansion into autoimmune diseases.

This is more than a record of a cancer revolution; it is a masterclass in the "platformization" of biotech. Whether you are an investor, a medical professional, or a tech enthusiast, this is an episode you cannot miss!

漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。

【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

2025 年 6 月，漢康生技宣佈與復宏漢霖達成抗癌新藥 HCB101 的區域授權，總金額突破 2 億美元。這不僅是漢康的重要里程碑，更證明了臺灣生技研發實力已具備國際競爭力。本集節目特別邀請漢康生技商務開發長（CBO）叢越華博士，他擁有德國有機化學博士背景，並曾主導過數十億美元的國際授權案。叢博士將分享：

• 科學與使命： 為什麼「先天免疫」是癌症治療的下一個關鍵？

• 授權內幕： 為什麼復宏漢霖願意投資一家僅成立 5 年的 Startup？

• 商戰策略： 專利保護（IP）如何從不同層度構築企業護城河？

• 國際視野： 漢康生技如何從「0 到 1」跨入「1 到 100」的擴張期？

無論您是專業投資人，還是關注生醫創新的朋友，這場科學與商務的精彩對談都不容錯過。

In June 2025, HanchorBio achieved a major milestone by signing a $202 million regional licensing deal for HCB101 with Henlius. What makes a global pharmaceutical giant bet on a 5-year-old startup?
In this episode, we sit down with Dr. Yuahua Cong, CBO of HanchorBio. With a PhD in Organic Chemistry from Germany and a track record of leading billion-dollar international deals, Dr. Chong shares insights into:

• The Science: Why innate immunity is the missing piece in the cancer immunotherapy puzzle.

• The Partnership: Why Henlius was chosen as the strategic partner for Greater China.

• IP Strategy: How HanchorBio builds a "moat" around its technology through multi-layered patent protection.

• Scaling Up: Why HanchorBio has already moved beyond the "Proof of Concept" phase into a global expansion stage.

Join us for a deep dive into the intersection of groundbreaking science and high-stakes business negotiation.

漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。

【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

生技投資常被視為高風險的博弈，但在資深投資者眼中，這是一場關於「勝率」與「倍數」的賽局 。本集邀請漢康生技創辦人劉世高博士，以他帶領團隊研發出台灣首個獲歐盟批准創新藥的實戰經驗，剖析為何他選擇投入僅有 1.6% 企業敢挑戰的「多功能融合蛋白」賽道。

劉博士將分享生醫界獨特的「頭彩理論」：當一個標靶能同時啟動多種免疫機制，它的商業回報將不再是單一產品，而是具備全球競爭力的戰略資產。讓我們與漢康一起，看見數據背後的商業邏輯，讀懂這場正在發生的抗癌革命 。

While biotech investing is often viewed as a high-stakes gamble, seasoned investors see it as a calculated game of odds and multiples.
In this episode, we are joined by Dr. Scott Liu, founder of HanchorBio. Drawing on his battle-tested experience leading the team behind Taiwan’s first innovative drug to receive EU approval, he dissects his decision to enter the "multifunctional fusion protein" arena—a path fewer than 1.6% of companies dare to tread.

Dr. Liu unveils the biomedical sector’s unique "Jackpot Theory": when a single target can simultaneously trigger multiple immune mechanisms, the payoff transcends a mere product—it becomes a strategic asset with global competitiveness. Join us to uncover the business logic behind the data and decipher the anti-cancer revolution unfolding before our eyes.

漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。